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Abstract
Background: DNA vaccination has been shown to elicit specific cellular and humoral immune
responses to many different agents in a broad variety of species. However, looking at a commercial
use, the duration of the immune response against the vaccine is critical. Therefore the persistence
of the DNA vaccine, as well as its expression, should be investigated. We conducted these
investigations on a DNA vaccine against Chlamydophila psittaci, a Gram-negative intracellular
bacterium which causes respiratory disease in turkeys and humans. Previous studies showed that
the DNA vaccine confers partial protection against C. psittaci infection in turkeys. Turkeys were
injected intramuscularly with the DNA vaccine : a eukaryotic expression vector (pcDNA1::MOMP)
expressing the major outer membrane protein (MOMP) of an avian C. psittaci serovar D strain.
Over a period of 11 weeks, cellular uptake of the DNA vaccine was examined by PCR, transcription
of the insert by reverse transcript-PCR (RT-PCR) and mRNA translation by immunofluorescence
staining of muscle biopsies.
Results: The results indicate that the DNA vaccine persists in turkey muscle for at least 10 weeks.
Moreover, during this period of time MOMP was continuously expressed, as evidenced by the
immunofluorescence staining and RT-PCR.
Conclusion: Since C. psittaci infections occur at the age of 3 to 6 and 8 to 12 weeks, a vaccine
persistence of 10 weeks seems adequate. Therefore, further research should concentrate on
improving the elicited immune response, more specifically the cell-mediated immune response,
rather than prolonging the lifespan of the plasmid.
Background
Genetic vaccination with plasmid DNA expression vectors
encoding the sequence of a specific antigen offers a prom-
ising and practical approach for the induction of protec-
tive immunity. This type of vaccine has been shown to
induce a protective immune response against viral [1],
bacterial [2] and parasitic [3] diseases in a broad range of
species and has several important advantages over com-
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mercial vaccines, both subunit and live attenuated. First of
all, they induce major histocompatibility complex (MHC)
class I restricted CD8+ T-cell responses [4,5]. Secondly,
sufficient quantities of plasmid DNA can easily be pro-
duced in a relatively cost-effective manner, after which the
vaccine can be stored with relative ease [4,6]. Further-
more, DNA vaccines may overcome inherent unrespon-
siveness in neonatal animals and function in the presence
of maternally derived immunity [4].
However, not withstanding these advantages, some reser-
vations for commercial application remain. First, integra-
tion of the injected plasmid DNA into the genome of the
host cell could occur [5,7,8]. Secondly, repeated injections
could lead to an immunological tolerance [9] or induce
autoimmunity [10]. Thirdly, injected DNA could induce
an immune response against the plasmid backbone [11].
Finally, while the advantage of a long-time persistence
probably provides a long-term production and presenta-
tion of the protein to the immune system, there is a risk of
plasmid DNA residue in the poultry meat used for human
consumption. To address these last issues, we studied the
persistence and expression of pcDNA1::MOMP, a plasmid
DNA expression vector encoding the 'major outer mem-
brane protein' (MOMP) of Chlamydophila psittaci serovar
D strain 92/1293 [12] after intramuscular injection in
commercial turkeys. C. psittaci, a Gram-negative obligate
intracellular bacterium, is highly prevalent on European
turkey farms and causes respiratory infections. This results
in substantial economic losses due to expensive antibiotic
treatment, weight loss, increased mortality and condem-
nation at slaughter [13,14]. Up to now, no vaccine is avail-
able for C. psittaci in birds. However, previous studies
have extensively shown the elicited immune response and
protection of pcDNA1::MOMP against C. psittaci infection
in turkeys [15-18]. The duration of the MOMP expression
(and consequently the duration of the elicited immune
response) after intramuscular injection has not been stud-
ied yet.
Results
Detection of the plasmid DNA by PCR analysis
In order to assess the detection limit (sensitivity) of the
PCR, a ten-fold dilution series of the plasmid DNA
(spiked with turkey muscle DNA) was prepared. The PCR
reaction was conducted as described in methods. The
results indicated that the lower PCR detection limit was
34.4 fg of plasmid DNA (data not shown). Next, the same
PCR reaction was performed on DNA isolates of the tissue
samples taken at euthanasia. All PCR results for the DNA
isolates of the muscle tissues at the injection site were pos-
itive (for the 3 different DNA isolates as well as for the 3
repetitions) up to 7 weeks p.v. At 8 weeks p.v. only 1 out
of 3 isolates was positive. At 9 weeks p.v. none of the iso-
lates were positive, even after using a higher amount of
plasmid DNA to conduct the PCR. At 10 weeks p.v. two
out of 3 isolates were positive. At 11 weeks p.v. none of
the isolates were positive. The injected black ink could be
detected up to 10 weeks p.v. However, at 11 weeks p.v. the
injection site could no longer be visualised by the black
ink and sampling became more random (figure 1). No
DNA vaccine could be detected in the opposite (non-vac-
PCR detection of the plasmid DNA in muscle tissue of vaccinated turkeys Figure 1
PCR detection of the plasmid DNA in muscle tissue of vaccinated turkeys. Gel image representing the PCR-prod-
ucts, obtained by PCR on DNA extracted from muscle tissue at 8, 10 and 11 weeks p.v. (w8pv, w10pv and w11pv). The 3 dif-
ferent samples of the same date, visible on the gel, are 3 DNA extractions from the pooled stock of muscle tissue at the 
(presumed) injection site, on which the PCR was conducted. The arrows indicate where a band of 1084 bp is visible. The 
SmartLadder (Eurogentec) was used as molecular size marker (with bands of 200, 400, 600, 800, 1000, 1500, 2000, 2500, 3000, 
4000, 5000, 6000, 8000 and 10000 bp). DNA of non-vaccinated muscle tissue was used as a negative control (-) and the 
pcDNA1::MOMP vector as a positive control (+). At 8 weeks p.v., a band of 1084 bp could still be detected in 1 out of 3 DNA 
isolates and at 10 weeks p.v. in 2 out of 3 DNA isolates. At 11 weeks p.v. no band could be detected on the ethidium bromide 
stained gel.BMC Veterinary Research 2006, 2:18 http://www.biomedcentral.com/1746-6148/2/18
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cinated) muscle tissue of the vaccinated turkeys or in the
site of the same thigh, but remote from the injection site,
during the entire length of the experiment (data not
shown).
OmpA expression analyses
RNA was isolated from the pooled muscle samples (at the
site of injection), as well as from the non-vaccinated mus-
cle tissue and the spleen of the vaccinated turkeys. An RT-
PCR was performed 3 times on the same RNA sample. A
PCR product was detected in all samples taken at the
injection site, until 10 weeks p.v. No PCR product could
be detected at the day of vaccination or at 11 weeks p.v.
(figure 2 – lanes 3 to 13). No pcDNA1::MOMP-specific
mRNA could be detected in the non-vaccinated muscle
tissue of the vaccinated turkeys (figure 2 – lanes 14 to 16)
nor in the spleen (data not shown).
In situ immunodetection of the expressed MOMP
There was no rMOMP expression (no fluorescence)
detected in the negative control, nor in the non-vacci-
nated muscle tissue of the other thigh. On the other hand,
rMOMP could be detected in all cryosections of the vacci-
nated muscle tissue up to the end of the experiment, 11
weeks p.v. (data not shown). Figure 3 shows the presence
of the stained rMOMP (green fluorescent dots) in muscle
tissue (red cells), at the site of injection at 10 weeks p.v.
Discussion
This study is the first to prove a prolonged presence and
activity of the pcDNA1::MOMP vaccine in turkeys. Earlier
studies reported a persistence of DNA vaccines ranging
from 17 days [19] up to 2 years [20] in various species.
Differences in persistence can be attributed to several fac-
tors such as the route of administration, the dose, the
nature of the antigen, the animal species, etc. Studies have
shown that following intravenous, intracerebral or intra-
nasal DNA vaccination, rapid clearance was observed in
mice [21,22]. However, following intramuscular (i.m.) or
intradermal administration, Chun et al. reported persist-
ence up to 8 weeks [22]. Other studies also showed a
increased persistence in mice (8 months) in comparison
to chickens (17 days) after i.m. immunization with the
same amount of plasmid [19]. The latter can be explained
by the growth rate and size of the animals, as correct tissue
sampling in chickens becomes more difficult as the birds
grow larger. In the current experiment, tissue selection was
facilitated by simultaneous injection of black ink. This
allowed a more precise selection of the inoculated tissues,
which could explain the prolonged persistence of the
DNA vaccine used in this experiment.. At 10 weeks p.v.
however, the simultaneously injected black ink was no
longer visible. Probably, at this time, there was no more
DNA vaccine detection because the site of injection could
not be retrieved. Although there are currently no data
available suggesting a correlation between the adminis-
tered dose and the persistence, the four-fold higher dose
used in the current experiment compared to the dose used
by Morris-Downes et al. could contribute to the longer
persistence [19]. Moreover, in our experiment, higher
injection volumes were used.  Earlier studies showed that
higher hydrostatic pressure, resulting from a higher injec-
tion volume, enhanced the uptake of plasmid DNA by
muscle cells [23]. Furthermore, Morris-Downes et al. sug-
RT-PCR detection of mRNA in muscle tissue of vaccinated turkeys Figure 2
RT-PCR detection of mRNA in muscle tissue of vaccinated turkeys. Gel image representing the PCR results on 
cDNA, obtained from both vaccinated muscle tissue at the (presumed) site of injection from the day of vaccination (w0pv) to 
10 weeks p.v. (lanes 3 to 13) and muscle tissue of the opposite (non-vaccinated) thigh on weeks 1, 4 and 9 p.v. (lanes 14 to 16). 
The SmartLadder (Eurogentec) was used as a molecular size marker (Smart). MilliQ water was used as a negative control (lanes 
2 and 17) and cDNA, generated by RT-PCR from mRNA produced in vitro from pcDNA1::MOMP, as a positive control (lane 
2). A band of 850 bp could be detected by gel electrophoresis from 1 to 10 weeks p.v. after PCR on cDNA from vaccinated 
muscle tissues, at the (presumed) site of injection (lanes 4 to 13). No PCR products were obtained after performing a PCR on 
cDNA from muscle tissue of the opposite (non-vaccinated) thighs (lanes 14 to 16) or muscle tissue at the site of injection at 
the day of vaccination (lane 3).BMC Veterinary Research 2006, 2:18 http://www.biomedcentral.com/1746-6148/2/18
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gested that the nature of the antigen and its ability to
induce a strong immune response could influence its per-
sistence [19]. Next, the choice of the promotor could also
have an effect on gene expression, since Davis et al. discov-
ered a 1000-fold increase in gene expression when com-
paring the Rous Sarcoma Virus (RSV) promotor to the
Simian Virus 40 (SV40) promoter [24]. Finally, in 4 to 6
week-old mice a higher gene expression was observed in
comparison to 10 week-old mice [25], so the age of the
animals (and consequently the growth rate) can also play
a role in the persistence.
Conclusion
Since the lifespan of commercial turkeys is about 15
weeks and most C. psittaci infections occur at the age of 3
to 6 and 8 to 12 weeks [26], a persistence of 10 weeks
seems adequate. Secondly, in view of social hesitance con-
cerning DNA vaccination and the resulting transgenic ani-
mals, DNA vaccination should be carefully investigated.
Finally, previous experiments in 'specific pathogen free'
(SPF) turkeys already showed partial protection against C.
psittaci infection by pcDNA1::MOMP vaccination. There-
fore, the main focus of further research should be on
improving the elicited immune response, more specifi-
cally the cell-mediated immune response, rather than pro-
longing the lifespan of the plasmid.
Methods
2.1. Experimental set-up
The experimental design was evaluated and approved by
the Ethical Commission for Animal Experiments of the
K.U.Leuven. Fifty five 1-day old commercial 'Big 6' turkeys
were housed in open pens under a heating and lighting
scheme as in conventional rearing and received food and
water  ad libitum. Plasmid pcDNA1::MOMP was con-
structed by sticky-end ligation of the outer membrane pro-
tein A (ompA) gene of C. psittaci serovar D strain 92/1293
into the EcoRI site of pcDNA1 (Invitrogen) and purified
and quantified as described previously [12]. At 10 days of
age, turkeys were injected with a single dose of 100 µg of
pcDNA1::MOMP dissolved in 0,9% saline solution and
1% black Indian ink (Pelikan) in a total volume of 300 µl
into the central portion of the left thigh muscle (m. quad-
riceps). From 1 to 11 weeks post vaccination (p.v.), five
turkeys were euthanized each week. At the time of eutha-
nasia, 4 different tissue samples were taken from each ani-
mal. One sample from the muscle of the vaccinated thigh,
located near the black ink; another sample from the mus-
cle of the vaccinated thigh, but well away from the ink. A
third sample was taken from the non-vaccinated thigh
and finally, the spleen was collected. Tissues from the
same location, taken at the same day, were pooled.
2.2. Detection of the plasmid DNA by PCR analysis
Total DNA was extracted from 25 mg of the pooled mus-
cle samples by means of the QIAamp DNA Mini Kit (QIA-
GEN). For each time of euthanasia, the samples from the
Detection of rMOMP expression by immunofluorescence staining in muscle tissue of vaccinated turkeys Figure 3
Detection of rMOMP expression by immunofluorescence staining in muscle tissue of vaccinated turkeys. The 
pictures show muscle tissue of vaccinated turkeys, at the site of injection, at 10 weeks p.v., viewed under a microscope under 
different light conditions (magnified 25 times). Picture 'A' shows the muscle cells under visible light. Picture 'B' shows the pres-
ence of green fluorescent rMOMP (by FITC-labelled antibodies, indicated on several places by white arrows) on a red back-
ground of muscle cells (Evans' Blue) under light of a wavelength of 488 nm.BMC Veterinary Research 2006, 2:18 http://www.biomedcentral.com/1746-6148/2/18
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same tissue (position) were pooled. On that pool 3 DNA
isolations were performed. For each DNA isolate, the con-
centration and purity was checked by measuring the opti-
cal density (OD) at 260 nm and the OD(260 nm)/
OD(280 nm) respectively. Next, a PCR was performed on
100 ng of plasmid DNA, for each of the 3 DNA isolates.
For reproducibility, each PCR was performed 3 times. The
PCR reaction mixture contained 50 mM KCl, 20 mM Tris-
HCl (pH 8.3), 2 mM MgCl2, 0.1% Tween20, 200 µM of
each dNTP, 1.25 µM of each primer, SuperTaq buffer
(10x), 0.1 unit SuperTaq polymerase (5U/µl) and 100 ng
of plasmid DNA in a total volume of 50 µl. After an initial
denaturation at 95°C for 5 minutes, 35 cycles of one min
at 95°C, two minutes at 55°C and three minutes at 72°C,
with a final extension at 72°C for 5 minutes, were per-
formed. The used primers were the commercial primer T7
(5'-AATACGACTCACTATAGGG – 3'), located on the
pcDNA1 vector, and EXR05 (5'-TGCTAGACCAACTT-
GCCATT – 3'), located on the inserted ompA gene. This
provided a means to distinguish between the presence of
the DNA vaccine and an unexpected Chlamydophila infec-
tion. Amplification products should have a size of 1042
base pairs (bp). Before analysis of the samples, the sensi-
tivity of the PCR set up was determined by performing the
PCR on dilution series of the DNA vaccine spiked with
genomic DNA of muscle tissue.
2.3. OmpA expression analyses
Total RNA was extracted from the pooled muscle samples
by TRIzol™ (Invitrogen), a commercial protocol based on
the method of Chomczynski and Sacchi (1987), but with
an extra DNase treatment to remove plasmid and
genomic DNA. For each RNA isolate, the concentration
and purity was checked by measuring the OD at 260 nm
and the OD(260 nm)/OD(280 nm) respectively. cDNA
was generated from the RNA template using primer
EXR02 (5'-GGTTGAGCAATGCGGATAGTAT-3') and
Omniscript Reverse Transcriptase according to the QIA-
GEN RT-PCR System protocol. The cDNA was then ampli-
fied by PCR using the primers EXF03 (5'-
CCTGTAGGGAACCCAGCTAGAA-3') and EXR02, yield-
ing a 850-bp product. Both EXR02 and EXF03 are located
on the ompA gene. The PCR reaction was performed in a
total volume of 20 µl containing Taq buffer (10x), 2.5
units Taq polymerase (5U/µl), 2 mM MgCl2, 1 µM of each
primer and 0.2 µM of each dNTP. After an initial denatur-
ation at 95°C for 5 minutes, 35 cycli were performed
accordingly: 3 minutes at 95°C, 1 min at 51°C and 0.5
min at 72°C, followed by a final extension at 72°C for 5
minutes.
2.4. In situ immunodetection of the expressed MOMP
Four different cryostat sections (10 µm) of both the mus-
cle tissue at the site of injection and the non-vaccinated
muscle tissue of the other thigh were prepared for each
day of euthanasia. As a negative control, cryostat sections
of the muscle tissue of non-vaccinated animals were used.
The sections were examined by an indirect immunofluo-
rescence staining as described previously [12], using a
monoclonal antibody against a genus-specific epitope on
the MOMP of Chlamydiaceae.
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